Companies › Amplexd Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EGCG and Quinine Sulfate Vaginal Suppository (Dysplasix™) Natural polyphenol and alkaloid combination for local cervical immune stimulation | – | Phase 2 | High-risk HPV (Any Strain) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07572396 | EGCG and Quinine Sulfate Vaginal Suppository (Dysplasix™) | Phase 2 | High-risk HPV (Any Strain) | Infectious disease | Dec 2026 |
No annotated target.
–
Sano Chemicals Hyundai Bioscience KTH Biopharma Frantz Viral Therapeutics Grand Theravac Life Sciences (Nanjing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.